O
Oblenio BioBiotech
Oblenio Bio develops novel therapeutics for metabolic and inflammatory diseases using proprietary biology platforms.
$62MSeries B
Investor undisclosed
A $62M Series B for a metabolic/inflammatory biotech signals investors are still backing platform plays in this space, but the bar is clearly higher—they need differentiated biology, not just another GLP-1 me-too. If you're building in adjacent areas (diagnostics, digital health for metabolic disease, or supply chain for biotech), this validates that the category has real capital velocity, but you'll need a defensible angle to compete for that same investor attention.